-
Uncategorized2 months ago
FDA Policy Tracker 2026: Psychedelics get a boost
A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to...
-
Uncategorized2 months ago
Odyssey tests IPO waters anew after quitting quest last year
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
-
Uncategorized2 months agoLilly publishes data confirming Foundayo’s safety profile
Eli Lilly has shared positive topline results from the Phase III ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in...
-
Uncategorized2 months ago
[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services
This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time. Read More
-
Uncategorized2 months ago
Nektar’s long-term mid-stage alopecia data fuels Phase 3 plans
Nektar Therapeutics’ data from the extension phase of a failed Phase 2b alopecia trial just about met Wall Street analyst expectations, helping the biotech’s ambitions to...
-
Uncategorized2 months ago
Scientists stunned as bacteria rewire DNA machinery to shape cells
Cyanobacteria—ancient microbes that oxygenated Earth and made complex life possible—are still revealing surprises billions of years later. Scientists have now discovered that a molecular system once...
-
Uncategorized2 months ago
What actually drives speed in complex drug development programs
Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development. Read More
-
Uncategorized2 months ago
From Product to Patient in Nuclear Medicine: Why Vertical Integration Is Essential for a Competitive Advantage
From Product to Patient in Nuclear Medicine: Why Vertical Integration Is Essential for a Competitive Advantage
-
Uncategorized2 months ago
KRAS drugmakers take another, better swing at lung cancer
SAN DIEGO — In early cuts of data, the next iteration of KRAS drugs for lung cancer appears to bear more promise than the first. KRAS...
-
Uncategorized2 months ago
UCB plots epilepsy expansion with $650M Neurona cell therapy acquisition
UCB plans to pay $650 million to Neurona Therapeutics in a bid to broaden its clinical-stage epilepsy portfolio. The deal comes with as much as $500...
STAT+: Up and down the ladder: The latest comings and goings
FDA imposes import alert on Indian plant after inspectors flag GMP failings
